Agios Pharmaceuticals (AGIO) Equity Average (2013 - 2026)

Agios Pharmaceuticals has reported Equity Average for 14 years, with the latest figure at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 23.45% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (down 23.45% YoY), and the FY2025 full-year result was $1.4 billion, up 16.25% from the prior year.
• Equity Average for Q1 2026 stood at $1.2 billion, down from $1.2 billion in the prior quarter.
• The five-year high for Equity Average was $1.6 billion in Q4 2024, with the low at $702.2 million in Q2 2024.
• Historically, Equity Average has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2024.
• Annual changes were most pronounced in 2022 — Equity Average sank 41.98% — and 2025, when it jumped 101.94%.
• Agios Pharmaceuticals' Equity Average stood at $1.1 billion in 2022, then dropped by 21.07% to $848.9 million in 2023, then surged by 86.57% to $1.6 billion in 2024, then declined by 21.79% to $1.2 billion in 2025, then slipped by 7.07% to $1.2 billion in 2026.
• The last three Equity Average figures came in at $1.2 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.